For some mul­ti­ple myelo­ma pa­tients, Carvyk­ti cut risk of death by 45%

John­son & John­son and Leg­end Biotech’s CAR-T cell ther­a­py Carvyk­ti re­duced the risk of death by 45% com­pared to stan­dard of care at al­most three …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

Director of IT, Security

Viridian Therapeutics

Waltham, MA, USA